DisGeNET - a database of gene-disease associations

melanoma, C0025202

Variant: rs121913255 ×

Source: ALL

Results per page

Gene

Disease

Variant

Source

Association Type

Semantic type

Protein Class

Disease Class

Type

Original DB

Consequence

DSI _v

DPI _v

pLI

EI _vda

EL _gda

Score _vda

PMID

PMID Year

AF_EXOME

Num. PMIDs

Num. SNPs_gda

AF_GENOME

Variant

Gene

Risk Allele

Score _vda

Association Type

Original DB

Sentence supporting the association

PMID

PMID Year

dbSNP:

rs121913255

NRAS

0.700

CausalMutation

CLINVAR

Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

25157968

2014

dbSNP:

rs121913255

NRAS

0.700

CausalMutation

CLINVAR

Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

25157968

2014

dbSNP:

rs121913255

NRAS

0.700

CausalMutation

CLINVAR

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.

23569304

2013

dbSNP:

rs121913255

NRAS

0.700

CausalMutation

CLINVAR

Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma.

23538902

2013

dbSNP:

rs121913255

NRAS

0.700

CausalMutation

CLINVAR

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.

23614898

2013

dbSNP:

rs121913255

NRAS

0.700

CausalMutation

CLINVAR

Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma.

23538902

2013

dbSNP:

rs121913255

NRAS

0.700

CausalMutation

CLINVAR

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

23414587

2013

dbSNP:

rs121913255

NRAS

0.700

CausalMutation

CLINVAR

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.

23569304

2013

dbSNP:

rs121913255

NRAS

0.700

CausalMutation

CLINVAR

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.

23614898

2013

dbSNP:

rs121913255

NRAS

0.700

CausalMutation

CLINVAR

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

23414587

2013

dbSNP:

rs121913255

NRAS

0.700

CausalMutation

CLINVAR

SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor.

23076151

2012

dbSNP:

rs121913255

NRAS

0.700

CausalMutation

CLINVAR

SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor.

23076151

2012

dbSNP:

rs121913255

NRAS

0.700

CausalMutation

CLINVAR

First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.

22761467

2012

dbSNP:

rs121913255

NRAS

0.700

CausalMutation

CLINVAR

First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.

22761467

2012

dbSNP:

rs121913255

NRAS

0.700

CausalMutation

CLINVAR

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.

20179705

2010

dbSNP:

rs121913255

NRAS

0.700

CausalMutation

CLINVAR

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.

20179705

2010

dbSNP:

rs121913255

NRAS

0.700

CausalMutation

CLINVAR

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.

20130576

2010

dbSNP:

rs121913255

NRAS

0.700

CausalMutation

CLINVAR

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.

20130576

2010

dbSNP:

rs121913255

NRAS

0.700

CausalMutation

CLINVAR

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

18390968

2008

dbSNP:

rs121913255

NRAS

0.700

CausalMutation

CLINVAR

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

18390968

2008

dbSNP:

rs121913255

NRAS

0.700

CausalMutation

CLINVAR

Distinct sets of genetic alterations in melanoma.

16291983

2005

dbSNP:

rs121913255

NRAS

0.700

CausalMutation

CLINVAR

Distinct sets of genetic alterations in melanoma.

16291983

2005

dbSNP:

rs121913255

NRAS

0.700

CausalMutation

CLINVAR

Ras mutations in human melanoma: a marker of malignant progression.

8120410

1994

dbSNP:

rs121913255

NRAS

0.700

CausalMutation

CLINVAR

Ras mutations in human melanoma: a marker of malignant progression.

8120410

1994

dbSNP:

rs121913255

NRAS

0.700

CausalMutation

CLINVAR

N-ras mutations in human cutaneous melanoma from sun-exposed body sites.

2674680

1989